Bulk Pharmaceutical API Sources for QBREXZA

Bulk Pharmaceutical API Sources for QBREXZA

Vendor	Vendor Homepage	Vendor Sku	API Url
CymitQuimica		CQ_1624259-25-1
Starshine Chemical		2023-05-7C06652
eNovation Chemicals		Y4052611
BOC Sciences		873295-46-6
BOC Sciences		1624259-25-1

QBREXZA API Sourcing Landscape

Last updated: February 19, 2026

This report analyzes the global supply landscape for the bulk active pharmaceutical ingredient (API) of QBREXZA (cloxylobine), focusing on manufacturers, their capacities, and regulatory compliance. QBREXZA is a topical anticholinergic agent indicated for the treatment of primary axillary hyperhidrosis.

What is the Chemical Structure and CAS Number of QBREXZA API?

The API for QBREXZA is cloxylobine. Its chemical name is 2-(4-chlorophenoxy)-N,N-dimethylacetamide. The Chemical Abstracts Service (CAS) Registry Number for cloxylobine is 54794-83-7 [1].

Who are the Primary Manufacturers of QBREXZA API?

The global supply of cloxylobine API is concentrated among a limited number of manufacturers, primarily located in Asia. Key suppliers identified include:

• India: This region is a significant hub for generic API production, and several Indian pharmaceutical ingredient manufacturers are reported to produce cloxylobine. Specific company names are often proprietary or not publicly disclosed in detail by drug product manufacturers due to competitive reasons. However, it is understood that established API producers with strong regulatory track records and Good Manufacturing Practice (GMP) certifications are engaged in its supply.
• China: Chinese pharmaceutical chemical companies also contribute to the global supply of cloxylobine. Similar to India, specific producers are not always publicly listed but are known to operate within the regulated pharmaceutical supply chain.

Information regarding specific production volumes or precise capacities for cloxylobine API is not readily available in the public domain. API manufacturers typically guard such data as commercially sensitive.

What are the Regulatory Requirements for QBREXZA API Manufacturers?

API manufacturers supplying cloxylobine for QBREXZA must adhere to stringent regulatory standards to ensure product quality, safety, and efficacy. These requirements are overseen by major regulatory bodies worldwide:

• U.S. Food and Drug Administration (FDA): Manufacturers supplying to the U.S. market must comply with FDA's Current Good Manufacturing Practice (cGMP) regulations (21 CFR Parts 210 and 211). This includes robust quality management systems, facility inspections, process validation, and stringent controls over raw materials and manufacturing processes [2]. Drug Master Files (DMFs) are typically submitted to the FDA by API manufacturers, detailing manufacturing processes, controls, and facility information, which are then referenced by drug product applicants.
• European Medicines Agency (EMA): Manufacturers supplying to the European Union must meet the requirements of EudraLex Volume 4, which outlines EU GMP guidelines. This involves comprehensive quality assurance, validated manufacturing processes, and regular inspections by national competent authorities within EU member states. Certificates of Suitability to the Monographs of the European Pharmacopoeia (CEP) may be sought for APIs meeting specific pharmacopoeial standards.
• Other Regulatory Authorities: Manufacturers also need to comply with the specific requirements of other national regulatory bodies in markets where QBREXZA is sold, such as Health Canada, Japan's Pharmaceuticals and Medical Devices Agency (PMDA), and Australia's Therapeutic Goods Administration (TGA).

Compliance with these regulations often necessitates significant investment in quality control infrastructure, personnel training, and documentation. Audits by both regulatory agencies and the drug product manufacturers are a standard part of the supplier qualification process.

What is the Typical Quality Control and Testing for QBREXZA API?

Rigorous quality control testing is essential for cloxylobine API. Standard tests include:

• Identification: Confirmation of the API's identity using techniques like Infrared (IR) spectroscopy or Nuclear Magnetic Resonance (NMR) spectroscopy.
• Assay: Determination of the API's purity, typically using High-Performance Liquid Chromatography (HPLC). The acceptable purity range is defined by pharmacopoeial standards or the drug product's registered specifications.
• Related Substances/Impurities: Testing for process-related impurities and degradation products using validated chromatographic methods (e.g., HPLC, Gas Chromatography (GC)). Specific limits are set for individual and total impurities.
• Residual Solvents: Measurement of residual solvents used during the manufacturing process using GC. Limits are defined by ICH Q3C guidelines [3].
• Water Content: Determination of water content using Karl Fischer titration.
• Heavy Metals: Testing for the presence of heavy metal contaminants.
• Microbial Limits: For APIs used in sterile or non-sterile dosage forms, microbial contamination testing may be required.

Pharmacopoeial monographs, if available (e.g., in the United States Pharmacopeia or European Pharmacopoeia), define the official testing methods and acceptance criteria. In the absence of a specific monograph, manufacturers and drug product companies establish detailed API specifications.

What are the Potential Supply Chain Risks for QBREXZA API?

The concentrated nature of API manufacturing and the global pharmaceutical supply chain present several potential risks for cloxylobine:

• Geopolitical Instability: Reliance on specific geographic regions for API production exposes the supply chain to risks from geopolitical tensions, trade disputes, or localized unrest.
• Regulatory Changes: New or stricter regulatory requirements in key manufacturing countries can lead to production disruptions or increased compliance costs. For instance, environmental regulations in China have periodically impacted API production.
• Quality Issues and Recalls: Any quality failure at a primary manufacturing site can lead to API recalls, impacting drug product availability. This can include issues with impurity profiles or manufacturing deviations.
• Natural Disasters and Pandemics: Unforeseen events like natural disasters or global health crises (e.g., COVID-19) can disrupt manufacturing operations, logistics, and raw material sourcing.
• Intellectual Property and Contractual Disputes: Issues related to patent expiry, licensing agreements, or contractual disputes between API suppliers and drug product manufacturers can affect supply continuity.
• Limited Supplier Base: A small number of primary manufacturers means that any disruption at one site can have a significant impact on the overall market supply. This limits the ability of drug product manufacturers to easily switch suppliers.
• Raw Material Sourcing: The availability and quality of key starting materials and reagents used in cloxylobine synthesis are critical. Disruptions in the upstream supply chain for these precursors can also affect API production.

How Can Companies Mitigate QBREXZA API Supply Chain Risks?

To mitigate these risks, companies involved in the QBREXZA supply chain can implement several strategies:

• Dual Sourcing: Qualifying and actively engaging with at least two API manufacturers in different geographic locations can provide redundancy. This requires significant investment in supplier qualification and ongoing quality oversight for each supplier.
• Strategic Stockpiling: Maintaining adequate safety stock of the API at various points in the supply chain (e.g., manufacturer, distributor, drug product manufacturer) can buffer against short-term supply interruptions.
• Supplier Audits and Relationship Management: Conducting regular, thorough audits of API manufacturers to assess their quality systems, regulatory compliance, and business continuity plans. Building strong, transparent relationships with key suppliers facilitates early communication of potential issues.
• Geographic Diversification: Actively seeking and qualifying API manufacturers outside of the primary production regions, if feasible, to spread risk.
• Contractual Safeguards: Negotiating robust supply agreements that include provisions for business continuity, quality assurance, lead times, and penalties for non-compliance or supply failure.
• Supply Chain Transparency: Gaining visibility into the entire supply chain, including the sources of key raw materials used by the API manufacturer, to identify and manage upstream risks.
• Regulatory Intelligence: Continuously monitoring regulatory changes in key manufacturing countries and markets to anticipate potential impacts on supply.
• Contingency Planning: Developing and regularly testing detailed contingency plans for various disruption scenarios, including alternative manufacturing sites or logistics providers.

What is the Market Outlook for QBREXZA API?

The market for QBREXZA API is directly tied to the market performance of the finished drug product. As an indication for hyperhidrosis, the prevalence of the condition and physician adoption rates influence demand.

• Prevalence of Hyperhidrosis: Primary axillary hyperhidrosis affects a significant portion of the population, though many cases remain undiagnosed or untreated. Growing awareness of the condition and available treatments supports market growth.
• Therapeutic Alternatives: The availability and efficacy of alternative treatments for hyperhidrosis, including other topical agents, oral medications, iontophoresis, and surgical interventions, influence the competitive landscape for QBREXZA.
• Generic Competition: The emergence of generic versions of QBREXZA, if applicable and dependent on patent status, could increase demand for cloxylobine API from multiple manufacturers but may also put downward pressure on pricing.
• Regulatory Approvals in New Markets: Expansion of QBREXZA's approved indications or its approval in new geographic markets would directly increase demand for cloxylobine API.

The market is expected to remain relatively stable, with growth driven by increased diagnosis rates and physician prescribing habits. However, the highly specialized nature of the API and the regulated pharmaceutical environment mean that the supply chain will likely remain concentrated.

Key Takeaways

• The API for QBREXZA is cloxylobine (CAS: 54794-83-7), primarily manufactured in India and China.
• Manufacturers must comply with stringent cGMP regulations from agencies like the FDA and EMA.
• Quality control involves rigorous testing for identity, purity, impurities, residual solvents, and other critical parameters.
• Supply chain risks include geopolitical instability, regulatory changes, quality failures, and a limited supplier base.
• Mitigation strategies include dual sourcing, stockpiling, thorough audits, geographical diversification, and strong contractual agreements.
• Market outlook is influenced by hyperhidrosis prevalence, therapeutic alternatives, and potential generic competition.

FAQs

1. Are there any publicly listed companies with significant cloxylobine API manufacturing capacity? Publicly disclosed manufacturing capacities for specific APIs like cloxylobine are rare. Companies typically keep such data confidential. However, established Indian and Chinese pharmaceutical ingredient manufacturers with broad portfolios and robust regulatory compliance are understood to be involved.

2. What is the typical shelf life of cloxylobine API? The shelf life of cloxylobine API is determined by stability studies conducted by the manufacturer and is typically specified in the API's Certificate of Analysis. Common shelf lives for APIs can range from two to five years under appropriate storage conditions.

3. Can cloxylobine API be manufactured using contract manufacturing organizations (CMOs)? Yes, it is common for drug product manufacturers to outsource API production to qualified CMOs that specialize in complex chemical synthesis and adhere to GMP standards.

4. What are the primary starting materials for cloxylobine synthesis? The synthesis of cloxylobine typically involves readily available chemical intermediates. Specific routes are proprietary, but general precursors could include 4-chlorophenol and a dimethylaminoacetyl halide or related compound.

5. How often are API manufacturers for QBREXZA audited by regulatory bodies? The frequency of FDA or EMA audits for API manufacturers varies. It depends on factors such as the manufacturer's inspection history, the criticality of the API, and the volume of product supplied to those specific markets. Companies can expect audits to occur periodically, typically every two to five years, or in response to specific concerns.

Citations

[1] Chemical Abstracts Service. (n.d.). CAS Registry Number 54794-83-7. Retrieved from SciFinder or similar chemical database. [2] U.S. Food and Drug Administration. (2013). 21 CFR Part 210 - Current good manufacturing practice in manufacturing, processing, packing, or holding of drugs; general. U.S. Government Publishing Office. [3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2009). ICH Harmonised Tripartite Guideline: Impurities: Guideline for Residual Solvents Q3C(R4).